Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Potentiation of bortezomib's Anti-Myeloma Effects in Combination with Anti-DR5 Agonistic Antibody: The Role of ER Stress in DR5 Editing and DR-Mediated Apoptotic Signaling

Hirokazu Miki, MD, Masahiro Abe, MD, PhD, Kumiko Kagawa, MD, Asuka Oda, PhD, Hiroe Amou, PhD, Akishige Ikegame, PhD, Keiichiro Watanabe, DDS, Masahiro Hiasa, DDS, Takeshi Harada, MD, Shiro Fujii, MD, Shingen Nakamura, MD, Ayako Nakano, MD, PhD, Kyoko Takeuchi, MD, PhD, Shuji Ozaki, MD, PhD, Yukimasa Shiotsu, PhD, Masaki Ri, MD, Shinsuke Iida, MD, PhD, Toshio Matsumoto, MD, PhD

Blood (2011) 118 (21): 5104.

https://doi.org/10.1182/blood.V118.21.5104.5104

Published: 2011

Journal Articles

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Significantly Enhances Myeloma Cell Cytotoxicity Via Antibody-Dependent Cellular Cytotoxicity

Takeshi Harada, MD, Shuji Ozaki, MD, PhD, Asuka Oda, PhD, Hiroe Amou, PhD, Shiro Fujii, MD, Shingen Nakamura, MD, Hirokazu Miki, MD, Ayako Nakano, MD, PhD, Kumiko Kagawa, MD, Kyoko Takeuchi, MD, PhD, Masahiro Abe, MD, PhD, Hironobu Shibata, MD, PhD, Shigeto Kawai, PhD, Hisafumi Yamada-Okabe, PhD, Toshio Matsumoto, MD, PhD

Blood (2011) 118 (21): 1833.

https://doi.org/10.1182/blood.V118.21.1833.1833

Published: 2011

Journal Articles

Facilitation of Osteoblast Differentiation by ATF-4 Accumulation through Proteasome Inhibition.

Shingen Nakamura, Masahiro Abe, Qu Cui, Ayako Nakano, Asuka Oda, Hiroe Amou, Akishige Ikegame, Takeshi Harada, Masahiro Hiasa, Hirokazu Miki, Kumiko Kagawa, Kyoko Takeuchi, Kenichiro Yata, Shuji Ozaki, Toshio Matsumoto

Blood (2009) 114 (22): 1823.

https://doi.org/10.1182/blood.V114.22.1823.1823

Published: 2009

Journal Articles

GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-α converting enzyme (TACE)

Masahiro Hiasa, Masahiro Abe, Ayako Nakano, Asuka Oda, Hiroe Amou, Shinsuke Kido, Kyoko Takeuchi, Kumiko Kagawa, Kenichiro Yata, Toshihiro Hashimoto, Shuji Ozaki, Kenzo Asaoka, Eiji Tanaka, Keiji Moriyama, Toshio Matsumoto

Blood (2009) 114 (20): 4517–4526.

https://doi.org/10.1182/blood-2009-04-215020

Published: 2009

Includes: Supplemental data

Journal Articles

Anti-Myeloma Effects of γδ T Cells Are Hampered by Bone Marrow Stromal Cells but Resumed by Stromal Cell-Derived Osteoblasts.

Kenichiro Yata, Masahiro Abe, Asuka Oda, Hiroe Amou, Masahiro Hiasa, Kyoko Takeuchi, Shingen Nakamura, Osamu Tanaka, Hirokazu Miki, Ayako Nakano, Kumiko Kagawa, Shuji Ozaki, Toshio Matsumoto

Blood (2008) 112 (11): 1685.

https://doi.org/10.1182/blood.V112.11.1685.1685

Published: 2008

Journal Articles

SB431542, a TGF-Beta Receptor Kinase Inhibitor, Restores Bone Formation Which Ameliorates Myeloma-Induced Microenvironment.

Kyoko Takeuchi, MD, Masahiro Abe, MD, Asuka Oda, MT, Hiroe Amou, MT, Masahiro Hiasa, DDS, Jin Asano, MD, Kenichi Kitazoe, MD, Toshihiro Hashimoto, MD, Shuji Ozaki, MD, Shinsuke Kido, PhD, Daisuke Inoue, MD, Toshio Matsumoto, MD

Blood (2006) 108 (11): 3479.

https://doi.org/10.1182/blood.V108.11.3479.3479

Published: 2006

Journal Articles

Emerging of Valproic Acid as an Anti-Myeloma Agent.

Kenichi Kitazoe, MD, Masahiro Abe, MD, Masahito Choraku, MD, Kumiko Kagawa, MD, Jin Asano, MD, Kyoko Takeuchi, MD, Masahiro Hiasa, DDS, Toshihiro Hashimoto, MD, Shuji Ozaki, MD, Asuka Oda, MT, Hiroe Amou, MT, Toshio Matsumoto, MD

Blood (2006) 108 (11): 3482.

https://doi.org/10.1182/blood.V108.11.3482.3482

Published: 2006

NARROW

Potentiation of bortezomib's Anti-Myeloma Effects in Combination with Anti-DR5 Agonistic Antibody: The Role of ER Stress in DR5 Editing and DR-Mediated Apoptotic Signaling

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Significantly Enhances Myeloma Cell Cytotoxicity Via Antibody-Dependent Cellular Cytotoxicity

Facilitation of Osteoblast Differentiation by ATF-4 Accumulation through Proteasome Inhibition.

GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-α converting enzyme (TACE)

Anti-Myeloma Effects of γδ T Cells Are Hampered by Bone Marrow Stromal Cells but Resumed by Stromal Cell-Derived Osteoblasts.

SB431542, a TGF-Beta Receptor Kinase Inhibitor, Restores Bone Formation Which Ameliorates Myeloma-Induced Microenvironment.

Emerging of Valproic Acid as an Anti-Myeloma Agent.

Email alerts

ASH Publications

American Society of Hematology

Potentiation of bortezomib's Anti-Myeloma Effects in Combination with Anti-DR5 Agonistic Antibody: The Role of ER Stress in DR5 Editing and DR-Mediated Apoptotic Signaling

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Significantly Enhances Myeloma Cell Cytotoxicity Via Antibody-Dependent Cellular Cytotoxicity

Facilitation of Osteoblast Differentiation by ATF-4 Accumulation through Proteasome Inhibition.

GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-α converting enzyme (TACE)

Anti-Myeloma Effects of γδ T Cells Are Hampered by Bone Marrow Stromal Cells but Resumed by Stromal Cell-Derived Osteoblasts.

SB431542, a TGF-Beta Receptor Kinase Inhibitor, Restores Bone Formation Which Ameliorates Myeloma-Induced Microenvironment.

Emerging of Valproic Acid as an Anti-Myeloma Agent.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only